Your browser doesn't support javascript.
loading
Identifying luteolin as a potential drug for treating lung adenocarcinoma with COVID-19 affection based on integration analysis of pharmacology and transcriptome.
Peng, Ping; Li, Na; Zhang, Ni; Fu, Xiangning; Peng, Shu; Zhao, Yujie; Ai, Bo.
Affiliation
  • Peng P; Department of thoracic surgery, Tongji Hospital, Wuhan, 430000, China.
  • Li N; Shenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, 518000, China.
  • Zhang N; Department of thoracic surgery, Tongji Hospital, Wuhan, 430000, China.
  • Fu X; Department of thoracic surgery, Tongji Hospital, Wuhan, 430000, China.
  • Peng S; Department of thoracic surgery, Tongji Hospital, Wuhan, 430000, China.
  • Zhao Y; Shenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, 518000, China.
  • Ai B; Department of thoracic surgery, Tongji Hospital, Wuhan, 430000, China.
Curr Med Chem ; 2023 Sep 08.
Article in En | MEDLINE | ID: mdl-37694790
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Curr Med Chem Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Curr Med Chem Year: 2023 Document type: Article